Ken Fisher’s Corcept Therapeutics CORT Stock Holding History

Ken Fisher’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-89	Closed	-$1.98K	–	1186
2023 Q2	$1.98K	Buy	+89	New	+$2.05K	﹤0.01%	1148

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Ken Fisher's CORT Position: Q3 2023 in Review

Ken Fisher sold out of Corcept Therapeutics (CORT) in Q3 2023, closing a stake of 89 shares — an estimated $1.98K sold.

Ken Fisher first reported a position in CORT in Q2 2023 and held it in 1 quarter. The position peaked at $1.98K in Q2 2023. 246 funds tracked by Wall St. Rank hold CORT as of Q3 2023.

Ken Fisher reported no remaining Corcept Therapeutics position as of Q3 2023 after selling out during the quarter.
Ken Fisher sold 89 Corcept Therapeutics shares in Q3 2023, an estimated $1.98K.
Ken Fisher first reported a position in Corcept Therapeutics in Q2 2023 and held it in 1 quarter.
Ken Fisher's Corcept Therapeutics position peaked at $1.98K in Q2 2023.
246 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2023.

Based on Fisher Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.